A Post Hoc Analysis of KidneyIntelX and Cardiorenal Outcomes in Diabetic Kidney Disease.
Girish N NadkarniDipti TakaleBruce C NealKenneth W MahaffeyYshai YavinMichael K HansenFergus FlemingHiddo J Lambers HeerspinkSteven G CocaPublished in: Kidney360 (2022)
KidneyIntelX, a bioprognostic test for assessing risk of CKD progression, risk stratified individuals for kidney, heart failure, and death outcomes in the Canagliflozin Cardiovascular Assessment Study.Individuals scored as high risk seemed to derive more of benefit from treatment with canagliflozin versus placebo.These findings may serve to increase adoption of underutilized therapies for cardiorenal risk reduction in patients with diabetic kidney disease.